Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02371187
Recruitment Status : Completed
First Posted : February 25, 2015
Results First Posted : April 10, 2019
Last Update Posted : April 10, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Christopher Bell, Colorado State University

Brief Summary:
Exercise is frequently prescribed as a favorable lifestyle intervention to prevent/reverse type 2 diabetes. It is also prescribed in addition to concurrent pharmacological treatment, such as metformin. Recent data (animal and human) suggest that metformin may attenuate the favorable benefits of exercise training. In light of the physiological mechanism of Dapagliflozin (sodium-glucose co-transporter 2 (SGLT2) inhibition), one might speculate that rather than inhibit, it will augment the favorable adaptations to exercise training.

Condition or disease Intervention/treatment Phase
Physical Activity Drug: Dapagliflozin Drug: Placebo Phase 2

Detailed Description:

This is a randomized, placebo-controlled, double blind, repeated measures study. 30 sedentary adults will be recruited for participation and randomly assigned to one of two 12-week treatments: 1) supervised endurance exercise training 4 days per week plus daily oral administration of Dapagliflozin; 2) supervised endurance exercise training 4 days per week plus daily oral administration of placebo. Prior to and following completion of the treatment the following dependent variables will be quantified: a) maximal aerobic capacity; b) substrate utilization during standardized low-moderate intensity exercise; c) skeletal muscle aerobic enzyme activity; d) body composition; and, e) oral glucose tolerance, fasting glucose and insulin resistance.

The dose of Dapagliflozin will begin as 5 mg/day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to 10 mg/day for the remainder of the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?
Actual Study Start Date : June 2015
Actual Primary Completion Date : January 2018
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dapagliflozin
The dose of Dapagliflozin will begin as one 5 mg tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two 5 mg tablets per day for the remainder of the study.
Drug: Dapagliflozin
Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
Other Name: Farxiga

Placebo Comparator: Placebo
Matching placebo for Dapagliflozin 5 mg will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
Drug: Placebo
Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.




Primary Outcome Measures :
  1. Change From Baseline of Maximal Oxygen Uptake at Week 12 [ Time Frame: Baseline,12 weeks ]
    Indirect calorimetry

  2. Change From Baseline of Respiratory Exchange Ratio at Week 12 [ Time Frame: Baseline, 12 weeks ]
    The respiratory exchange ratio (RER) is the ratio between the amount of carbon dioxide (CO2) produced in metabolism and oxygen (O2) used during standardized exercise.

  3. Change From Baseline of Maximal Aerobic Enzyme Activities in Skeletal Muscle at Week 12 [ Time Frame: Baseline, 12 weeks ]
    Maximal citrate synthase activity in skeletal muscle sample

  4. Change From Baseline of Insulin Sensitivity at Week 12 [ Time Frame: Baseline, 12 weeks ]
    Insulin Sensitivity was estimated by measuring circulating glucose and insulin concentrations after a 12-hour fast and after ingestion of 75 g of glucose. Glucose was measured 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes after glucose ingestion. Insulin was measured 15, 30, 45, 60, 90 and 120 minutes after glucose ingestion. Insulin sensitivity was estimated using the Matsuda Index, represented by the formula: Matsuda index = 10,000/SQRT [fasting glucose*fasting insulin* (mean glucose from time 5, 10, 15, 20, 30, 45, 60, 75, 90, 105 and 120 minutes) * (mean insulin from time 15, 30, 45, 60, 90 and 120 minutes)], with higher numbers indicating better insulin sensitivity.

  5. Change From Baseline of Fat Free Mass at Week 12 [ Time Frame: Baseline, 12 weeks ]
    Via dual energy X-ray absorptiometry



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Provision of informed consent prior to any study specific procedures.
  2. No known Type 2 Diabetes.
  3. Body mass index 25-45 kg/m^2
  4. Sedentary (maximum of 2/week regularly scheduled activity sessions of < 20 minutes during the previous 2 years).
  5. Completion of a screening visit consisting of medical history, physical examination, and 12-lead electrocardiogram and blood pressure assessment at rest and during incremental exercise to volitional exhaustion (Note: Subjects with abnormal screening values may be eligible if the results are not clinically significant, as judged by the investigator or medical monitor).
  6. Agree to abide by the study schedule and to return for the required assessments.
  7. Be willing and able to repeatedly perform exercise.
  8. Women of childbearing potential must have negative pregnancy test and be using acceptable contraception.

Exclusion Criteria:

Subjects should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Evidence of clinically significant cardiovascular, respiratory, renal, hepatic, pulmonary, gastrointestinal, hematological, neurological, psychiatric, or other disease that may interfere with the objectives of the study or the safety of the subject, as judged by the investigator in agreement with the sponsor or medical monitor, have been hospitalized in the past 2 years as a result of these conditions, or are receiving pharmacological treatment for these conditions.
  2. Use of prescription drugs (see exceptions listed below) or herbal preparations in the 4 weeks before study commencement.

    Permitted Prescription Drugs

    • Birth Control
    • Less than 7 days, short course antibiotics. Note: Rifampin is not permitted.
    • Other medicines, for gastroesophageal reflux disease (GERD), depression, seasonal allergies and over-the-counter analgesics, may be allowed, but will be approved on a case-by-case basis.
  3. Is currently enrolled in another clinical study for another investigational drug or has taken any other investigational drug within 30 days before the screening visit.
  4. Habitual and/or recent use (within 2 years) of tobacco.
  5. Being considered unsuitable for participation in this trial for any reason, as judged by the investigator or medical monitor.
  6. History of serious hypersensitivity reaction to Dapagliflozin.
  7. Severe renal impairment, end-stage renal disease, or dialysis.
  8. Pregnant or breastfeeding patients.
  9. Severe hepatic insufficiency and/or significant abnormal liver function defined as aspartate aminotransferase (AST) >3x upper limit of normal and/or alanine aminotransferase (ALT) >3x upper limit of normal.
  10. Total bilirubin >2.0 mg/dL (34.2 umol/L).
  11. Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody Immunoglobulin M, Hepatitis B surface antigen and Hepatitis C virus antibody.
  12. Estimated Glomerular Filtration Rate <60 mL/min/1.73 m^2 (calculated by Cockcroft-Gault formula).
  13. History of bladder cancer.
  14. Recent cardiovascular events in a patient, including any of the following: acute coronary syndrome within 2 months prior to enrollment; hospitalization for unstable angina or acute myocardial infarction within 2 months prior to enrolment; acute stroke or trans-ischemic attack within two months prior to enrollment; less than two months post coronary artery re-vascularization; congestive heart failure defined as New York Heart Association class IV, unstable or acute congestive heart failure. Note: eligible patients with congestive heart failure,especially those who are on diuretic therapy, should have careful monitoring of their volume status throughout the study.
  15. Blood pressure at enrollment: Systolic blood pressure ≥165 mmHg and/or diastolic blood pressure ≥100 mmHg.
  16. Blood pressure at randomization: Systolic blood pressure ≥165 mmHg and/or diastolic blood pressure ≥100 mmHg
  17. Patients who, in the judgment of the medical monitor, may be at risk for dehydration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02371187


Locations
Layout table for location information
United States, Colorado
Colorado State University, Dept. of Health and Exercise Science
Fort Collins, Colorado, United States, 80523-1582
Sponsors and Collaborators
Christopher Bell
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Christopher Bell, PhD Colorado State University
  Study Documents (Full-Text)

Documents provided by Christopher Bell, Colorado State University:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Christopher Bell, Associate Professor, Colorado State University
ClinicalTrials.gov Identifier: NCT02371187    
Other Study ID Numbers: 14-5529H
First Posted: February 25, 2015    Key Record Dates
Results First Posted: April 10, 2019
Last Update Posted: April 10, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Sodium-Glucose Transporter 2 Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents
Physiological Effects of Drugs